We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+3.02%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$751M
AUM Growth
-$32.5M
Cap. Flow
+$2.11M
Cap. Flow %
0.28%
Top 10 Hldgs %
35.59%
Holding
104
New
11
Increased
46
Reduced
31
Closed
15

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$22.1M
2
SYK icon
Stryker
SYK
+$18.4M
3
VRDN icon
Viridian Therapeutics
VRDN
+$14.4M
4
MCK icon
McKesson
MCK
+$12.9M
5
UNH icon
UnitedHealth
UNH
+$11.4M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$23.8M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$16.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$12.7M
4
LLY icon
Eli Lilly
LLY
+$10.1M
5
UTHR icon
United Therapeutics
UTHR
+$9.76M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
26
Replimune Group
REPL
$1.28B
$10.5M 1.4%
869,759
+106,012
+14% +$1.29M
RXST icon
27
RxSight
RXST
$294M
$10.3M 1.38%
300,698
+116,378
+63% +$5.25M
EWTX icon
28
Edgewise Therapeutics
EWTX
$4.73B
$10.2M 1.36%
381,173
-275,897
-42% -$8.78M
UNH icon
29
UnitedHealth
UNH
$364B
$10.1M 1.35%
+20,000
New +$11.4M
NRIX icon
30
Nurix Therapeutics
NRIX
$2.76B
$10M 1.34%
532,172
+93,201
+21% +$2.14M
PCVX icon
31
Vaxcyte
PCVX
$8.88B
$9.51M 1.27%
116,138
-14,111
-11% -$1.4M
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$30B
$9.1M 1.21%
38,672
+13,187
+52% +$3.47M
CSTL icon
33
Castle Biosciences
CSTL
$960M
$8.12M 1.08%
304,629
+8,558
+3% +$261K
LIVN icon
34
LivaNova
LIVN
$4.45B
$8.1M 1.08%
174,934
+73,205
+72% +$3.75M
CVS icon
35
CVS Health
CVS
$121B
$8.08M 1.08%
+180,000
New +$10.1M
PTCT icon
36
PTC Therapeutics
PTCT
$6.06B
$8.01M 1.07%
177,368
-17,632
-9% -$755K
QDEL icon
37
QuidelOrtho
QDEL
$1.02B
$7.81M 1.04%
175,415
+100,415
+134% +$4.11M
XENE icon
38
Xenon Pharmaceuticals
XENE
$6.31B
$7.57M 1.01%
193,004
+1,346
+0.7% +$55.7K
FOLD
39
DELISTED
Amicus Therapeutics
FOLD
$7.39M 0.98%
784,376
+179,058
+30% +$1.86M
SNDX icon
40
Syndax Pharmaceuticals
SNDX
$1.77B
$6.97M 0.93%
526,973
+18,690
+4% +$320K
DXCM icon
41
DexCom
DXCM
$34.3B
$6.11M 0.81%
78,550
+7,962
+11% +$589K
AXGN icon
42
Axogen
AXGN
$2.67B
$6.03M 0.8%
365,703
-47,185
-11% -$668K
KROS icon
43
Keros Therapeutics
KROS
$222M
$4.98M 0.66%
314,541
-107,241
-25% -$5.57M
BCYC
44
Bicycle Therapeutics
BCYC
$284M
$4.93M 0.66%
352,481
-92,915
-21% -$1.99M
QURE icon
45
uniQure
QURE
$3.13B
$4.86M 0.65%
+275,000
New +$2.37M
JAZZ icon
46
Jazz Pharmaceuticals
JAZZ
$16.2B
$4.65M 0.62%
37,751
-34,505
-48% -$4.07M
TERN
47
DELISTED
Terns Pharmaceuticals
TERN
$4.59M 0.61%
829,105
+283,354
+52% +$1.92M
TEVA icon
48
Teva Pharmaceuticals
TEVA
$42.8B
$4.34M 0.58%
196,805
-88,489
-31% -$1.61M
RARE icon
49
Ultragenyx Pharmaceutical
RARE
$2.65B
$4.21M 0.56%
100,159
-9,309
-9% -$462K
VCYT icon
50
Veracyte
VCYT
$3.59B
$3.97M 0.53%
100,301
-28,959
-22% -$1.1M
1
2
3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Parkman Healthcare Partners held 104 positions worth $751M, down 4.2% from $783M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners's Q4 2024 filing shows 11 new, 46 increased, 31 reduced and 15 closed positions. Its largest new stake was McKesson: 23,000 shares worth $13.1M. The largest sale was Teleflex, an estimated $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Parkman Healthcare Partners's largest Q4 2024 buy was McKesson: 23,000 shares worth $13.1M.
  • Parkman Healthcare Partners added most to Gilead Sciences in Q4 2024, an estimated $22.1M increase.
  • Parkman Healthcare Partners's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $10.1M.
  • Parkman Healthcare Partners fully exited Teleflex in Q4 2024, selling an estimated $23.8M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $751M portfolio in Q4 2024.
  • Parkman Healthcare Partners opened 11 new positions and closed 15 in Q4 2024.
  • Parkman Healthcare Partners's portfolio value fell 4.2% quarter-over-quarter to $751M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2024, filed 14 Feb 2025.